Codexis, Inc.’s Post

🌟 Exciting September Ahead for CPC Scientific! 🌟 We’re thrilled to announce that CPC Scientific, a leading manufacturer of oligonucleotides and peptides, will be showcasing our expertise and solutions at several major industry events this September: 💡 RNA Leaders (Sept 4-5) 🔬 ChemOutsourcing (Sept 3-6) 🧬 Oligonucleotide Therapeutics and Delivery (Sept 9-10) 🌟 Boulder Peptide Symposium (Sept 16-19) As a trusted partner in oligonucleotide and peptide manufacturing, we look forward to connecting with industry peers, sharing our latest advancements, and exploring new collaborations. Whether you're interested in our advanced oligonucleotide synthesis or innovative peptide solutions, we invite you to visit our booths and meet with our business development team members to discover how CPC Scientific can support your next project. Stay tuned for more details on our participation and how to engage with us. We look forward to seeing you at these exciting events! #CPCScientific #OligonucleotideManufacturing #PeptideManufacturing #ChemOutsourcing #OligonucleotideTherapeutics #RNALeaders #BoulderPeptideSymposium #Biotech #Pharma #Innovation #Networking #TradeShows

I am so proud to be part of a team that holds science innovation at the forefront of their business model! Ask me today how our humanized animal models can accelerate your preclinical research. #cancer #humanizedmice #oncology #AACR #immunology

Thanks to everyone who joined and asked questions at our seminar with N=1 Collaborative yesterday! Our Chief Technology Officer, David Butler, spoke on a panel of experts about "Control of regulatory starting material quality for oligonucleotide therapeutics". During the talk, David provided insights into the synthesis of phosphoramidites, a systematic approach to categorizing phosphoramidite impurities, and analytical techniques for purity and impurities characterization and measurement of amidites used in N=1 oligonucleotides. Did you miss it? Don't worry, you can catch up with the recording on-demand via the link below. 👇 https://loom.ly/4n4G4Kw #Oligonucleotides #PharmaEvent #CDMO

With major collaborations and partnership deals involving companies like C4 Therapeutics, Inc. , Merck, Monte Rosa Therapeutics and more, and significant progress in the clinic with BTK degraders and other assets, it’s crucial to unite at the 7th TPD & Induced Proximity Summit taking place in Boston this October. The longest standing and most comprehensive protein degradation and proximity conference will span everything from foundational research and discovery to IND-filing and clinical trials, allowing a deep dive into the opportunities and challenges in expanding the target space and developing therapeutically relevant degraders, blockers, stabilisers, and inducers of protein-protein interactions. Uniting over 550 enthusiasts from across the field, we will be providing a comprehensive view of protein degradation and modulation research, including SureTACs, EpiTACs, RIPTACs, Molecular Gates, and more, allowing you to network with experts in the space, benchmark against competitors and stay ahead of the curve. 💬 Interested in getting involved? Email me at anika.johal@hansonwade.com or message me via LinkedIn and I will be happy to share the agenda! #proteindegradation #TPD #targetedproteindegradation #inducedproximity #WomenInTPD #molecularglues #partnershipsinTPD

When it comes to biologics development, biophysical stability characterization tools must be versatile, so that you’re able to tackle any type of project that comes your way. Expert Nathan Wallace, Ph.D. shares just some of the many protein types that work with Prometheus Panta for simultaneous, multi-parameter assessment of thermal and colloidal stability. With the versatility of Prometheus Panta, your lab will be future-proofed and ready to handle new biologics modalities. Learn more about Prometheus Panta and its applications: https://lnkd.in/gR5rr5QZ

Join Vector Laboratories, Inc. for an exciting webinar regarding influencing ADC performance through linker design. Register below and set a reminder for May 21st at 2pm EDT! Don't miss out! #lifescience #ADC #biotechnology

Register for our webinar next month to learn more about how our portfolio of linkers is expanding the potential and effectiveness of antibody drug conjugates!

🌟 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗨𝗺𝗮𝗯𝘀𝗗𝗕 𝗼𝗻 𝗔𝗯𝗶𝗻𝘃𝗶𝘃𝗼, 𝗮 𝗕𝗶𝗼𝗶𝗻𝘁𝗿𝗼𝗻 𝗯𝗿𝗮𝗻𝗱 🌟 UmabsDB is a leading database for antibody therapeutics, providing detailed information on the development, origin, target, indication, sequence, patent, and clinical status of antibodies. Abinvivo is a Biointron brand that provides catalog products for in vivo research with the ease of online ordering. Simply create an account on the Abinvivo website and navigate to UmabsDB in the menu bar. Use the database for free by registering now–dive into the wealth of information UmabsDB provides! Register now here 👉 https://lnkd.in/e_bfaACy #Biointron #Biotech #Supplier #Antibody #DrugDevelopment #Database

🔍 Need to accelerate your drug discovery program? Let us help you. BPS Bioscience Inc. offer screening services to quickly identify potential therapeutics, predict potency, and narrow down large pools of candidates to much smaller ones. Additionally, cell-based screening services are also available for a more comprehensive view of the biological context and resulting cellular responses. Follow the link for more information 👇 https://lnkd.in/ei9wwpMA #DrugDiscovery #Bioscience

🌟 Shaperon: Innovating Biotech Solutions 🌟 Shaperon is advancing treatments through its unique inflammatory complex inhibitors and nanobody technology. Key Pipelines: NuGel: Atopic dermatitis treatment in Phase 2 trials in the US, following success in Korea. NuCerin: Alzheimer’s treatment in Phase 1 trials in Korea. Papiliximab: Dual-target immuno-oncology drug nearing technology transfer post-preclinical success. With growing investments in R&D, Shaperon is positioned to lead in the global atopic dermatitis market. NuGel’s innovative mechanism and strong safety profile aim to surpass existing therapies. Despite financial challenges, Shaperon’s advancements in clinical trials and strategic partnerships offer promising growth potential. 🚀 Stay tuned for updates as we continue our journey of innovation! #Biotech #ClinicalTrials #Innovation #AtopicDermatitis #Shaperon #NuGel https://lnkd.in/eZDym5nW